Advertisement
U.S. markets open in 2 hours 21 minutes
  • S&P Futures

    5,071.25
    -9.75 (-0.19%)
     
  • Dow Futures

    38,894.00
    -99.00 (-0.25%)
     
  • Nasdaq Futures

    17,889.25
    -26.00 (-0.15%)
     
  • Russell 2000 Futures

    2,049.10
    +5.70 (+0.28%)
     
  • Crude Oil

    78.25
    -0.29 (-0.37%)
     
  • Gold

    2,038.00
    -4.70 (-0.23%)
     
  • Silver

    22.56
    -0.08 (-0.34%)
     
  • EUR/USD

    1.0835
    -0.0007 (-0.07%)
     
  • 10-Yr Bond

    4.2740
    0.0000 (0.00%)
     
  • Vix

    14.00
    +0.16 (+1.16%)
     
  • GBP/USD

    1.2648
    -0.0012 (-0.10%)
     
  • USD/JPY

    149.9620
    -0.6710 (-0.45%)
     
  • Bitcoin USD

    62,492.69
    +3,396.88 (+5.75%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,649.72
    +24.74 (+0.32%)
     
  • Nikkei 225

    39,166.19
    -41.84 (-0.11%)
     

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc.

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences.

Jefferies London Healthcare Conference
Date: Tuesday, November 14 – Thursday, November 16, 2023
Location: The Waldorf Hilton, London, UK

Piper Sandler & Co. Annual Healthcare Conference
Date: Tuesday, November 28 – Thursday, November 30, 2023
Location: The Lotte New York Palace, New York, NY

Links to the presentations and webcast will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.

About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com

Matthew Purcell, Pharm.D.
Media Inquiries
Russo Partners, LLC
matthew.purcell@russopartnersllc.com


Advertisement